New York, NY -- (SBWIRE) -- 01/06/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: DARA Biosciences Inc (NASDAQ:DARA), XOMA Corp (NASDAQ:XOMA), Frontline Ltd (NYSE:FRO), McEwen Mining Inc (NYSE:MUX)
DARA Biosciences Inc (NASDAQ:DARA) showed a volume of 1.99 million shares by the end of last trade whereas the average volume of the stock remained 888,256.00 shares. The stock opened the session at $0.60 but then moved to $0.610. At that price, the stock showed a positive performance of 3.39%. DARA BioSciences, Inc. is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care pharmaceutical products. The Company has the exclusive United States marketing rights to its Soltamox (oral liquid tamoxifen). As of December 31, 2011, the Company continues to have an internal clinical development program for its two drug candidates, which cleared investigational new drug applications from the Food and Drug Administration (FDA), KRN5500 and DB959.
Will DARA Continue To Move Higher? Find Out Here
XOMA Corp (NASDAQ:XOMA) opened the session at $6.93 and closed the session at $7.09. The stock showed a positive performance of 2.46% in previous trading session. Traded with volume of 1.98 million shares in the prior session and the average volume of the stock remained 2.46 million shares. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052), a humanized monoclonal allosteric modulating antibody designed to inhibit the pro-inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company’s preclinical pipeline includes classes of antibodies that activate or sensitize the insulin receptor in vivo, named XMet, and represent potential new therapeutic approaches to the treatment of diabetes and several diseases that have insulin involvement.
For How Long XOMA will fight for Profitability? Read This Trend Analysis report
Frontline Ltd (NYSE:FRO) opened the session at $3.71 and closed the session at $3.80. The stock showed a positive performance of 5.85% in previous trading session. Traded with volume of 1.96 million shares in the prior session and the average volume of the stock remained 1.77 million shares. The beta of the stock remained 2.05. Frontline Ltd. is a Bermuda-based shipping company engaged primarily in the ownership and operation of oil tanker. The Company operates oil tankers of two sizes: Very Large Crude Carriers (VLCCs), which are between 200,000 and 320,000 deadweight tonnages (dwt), and Suezmax tankers, which are vessels between 120,000 and 170,000 dwt. The Company operates through subsidiaries and partnerships located in the Bahamas, Bermuda,
Why Should Investors Buy FRO After The Recent Gain? Just Go Here and Find Out
McEwen Mining Inc (NYSE:MUX) the stock decreased -1.41% and finished the session at $2.10. Traded with volume of 1.92 million shares in the prior session and the average volume of the stock remained 2.20 million shares. The beta of the stock remained -0.23. McEwen Mining Inc. (McEwen Mining), formerly US Gold Corporation, is engaged in the exploration for and production of precious metals in the United States, Mexico and Argentina. McEwen Mining’s operating segments include USA and Mexico. The Company holds an interest in numerous exploration and development stage properties and projects in Nevada, Mexico and Argentina, as well as a 49% equity interest in the gold-silver San Jose Mine in Santa Cruz Province,
Will MUX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)